
    
      Since the HZ/su vaccine has not yet been licensed and marketed, this study is being conducted
      to enable potentially eligible subjects who previously received placebo in ZOSTER-006
      (NCT01165177) or ZOSTER-022 (NCT01165229) to receive the HZ/su vaccine.

      Study ZOSTER-056 is an open-label, multi-centric and single arm study to cross-vaccinate and
      collect safety data in terms of of unsolicited Adverse Events (AEs), Serious Adverse Events
      (SAEs) and pIMD from subjects >= 50 YOA who previously received placebo.
    
  